|
Gene: TBC1D13 |
Gene summary for TBC1D13 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TBC1D13 | Gene ID | 54662 |
Gene name | TBC1 domain family member 13 | |
Gene Alias | TBC1D13 | |
Cytomap | 9q34.11 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R8B1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54662 | TBC1D13 | HCC1_Meng | Human | Liver | HCC | 5.95e-17 | -1.02e-02 | 0.0246 |
54662 | TBC1D13 | HCC2_Meng | Human | Liver | HCC | 2.20e-03 | 1.08e-02 | 0.0107 |
54662 | TBC1D13 | HCC1 | Human | Liver | HCC | 1.02e-04 | 3.66e+00 | 0.5336 |
54662 | TBC1D13 | HCC2 | Human | Liver | HCC | 9.62e-03 | 3.49e+00 | 0.5341 |
54662 | TBC1D13 | HCC5 | Human | Liver | HCC | 8.77e-03 | 1.61e+00 | 0.4932 |
54662 | TBC1D13 | S014 | Human | Liver | HCC | 5.31e-06 | 2.36e-01 | 0.2254 |
54662 | TBC1D13 | S015 | Human | Liver | HCC | 8.66e-11 | 4.14e-01 | 0.2375 |
54662 | TBC1D13 | S016 | Human | Liver | HCC | 1.65e-07 | 2.39e-01 | 0.2243 |
54662 | TBC1D13 | S028 | Human | Liver | HCC | 6.05e-07 | 3.20e-01 | 0.2503 |
54662 | TBC1D13 | S029 | Human | Liver | HCC | 1.74e-09 | 3.77e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TBC1D13 | SNV | Missense_Mutation | novel | c.28N>A | p.Ala10Thr | p.A10T | Q9NVG8 | protein_coding | tolerated(0.16) | benign(0.081) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
TBC1D13 | SNV | Missense_Mutation | novel | c.92N>C | p.Phe31Ser | p.F31S | Q9NVG8 | protein_coding | tolerated(0.35) | benign(0.135) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TBC1D13 | SNV | Missense_Mutation | c.104N>A | p.Pro35His | p.P35H | Q9NVG8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TBC1D13 | SNV | Missense_Mutation | c.352N>A | p.Glu118Lys | p.E118K | Q9NVG8 | protein_coding | tolerated(0.1) | benign(0.234) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TBC1D13 | SNV | Missense_Mutation | novel | c.325N>T | p.Arg109Trp | p.R109W | Q9NVG8 | protein_coding | deleterious(0) | possibly_damaging(0.586) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TBC1D13 | SNV | Missense_Mutation | rs746949349 | c.251N>T | p.Ala84Val | p.A84V | Q9NVG8 | protein_coding | deleterious(0.04) | benign(0.071) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
TBC1D13 | SNV | Missense_Mutation | c.1072A>G | p.Met358Val | p.M358V | Q9NVG8 | protein_coding | deleterious(0) | possibly_damaging(0.868) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD | |
TBC1D13 | SNV | Missense_Mutation | novel | c.68N>C | p.Leu23Ser | p.L23S | Q9NVG8 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-37-A5EN-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
TBC1D13 | SNV | Missense_Mutation | novel | c.264N>T | p.Met88Ile | p.M88I | Q9NVG8 | protein_coding | tolerated(0.43) | benign(0) | TCGA-NC-A5HP-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | PD |
TBC1D13 | SNV | Missense_Mutation | novel | c.885N>C | p.Leu295Phe | p.L295F | Q9NVG8 | protein_coding | deleterious(0.04) | probably_damaging(0.993) | TCGA-CV-6940-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |